• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Was This Acquisition a Smart Move for GlaxoSmithKline?

cafead

Administrator
Staff member
  • cafead   May 15, 2022 at 11:12: PM
via
  • Momelotinib could be a potent treatment for bone marrow cancer patients.
  • The drug candidate could also become a blockbuster for GlaxoSmithKline.
  • Shares of the drugmaker seems like a good long-term buy for investors.

article source
 

<